While We Wait: EnVivo Compound Slowed Cognitive Decline In Phase II Alzheimer’s Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
EVP-6124, a partial agonist of the alpha-7 nicotinic receptor, had a statistically significant effect on both cognition and clinical function in Phase IIb data presented at the Alzheimer’s Association International Conference in Vancouver; pivotal trials are in the works.